ING Groep NV Increases Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

ING Groep NV grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 459.2% in the 4th quarter, HoldingsChannel reports. The firm owned 93,026 shares of the medical equipment provider’s stock after acquiring an additional 76,389 shares during the quarter. ING Groep NV’s holdings in Zimmer Biomet were worth $9,826,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Ieq Capital LLC increased its position in shares of Zimmer Biomet by 65.6% during the 4th quarter. Ieq Capital LLC now owns 9,853 shares of the medical equipment provider’s stock valued at $1,041,000 after purchasing an additional 3,904 shares during the last quarter. Private Advisor Group LLC increased its holdings in Zimmer Biomet by 25.5% in the 4th quarter. Private Advisor Group LLC now owns 13,879 shares of the medical equipment provider’s stock worth $1,466,000 after acquiring an additional 2,822 shares during the last quarter. Venturi Wealth Management LLC increased its holdings in Zimmer Biomet by 950.3% in the 4th quarter. Venturi Wealth Management LLC now owns 1,859 shares of the medical equipment provider’s stock worth $196,000 after acquiring an additional 1,682 shares during the last quarter. D.A. Davidson & CO. increased its holdings in Zimmer Biomet by 36.4% in the 4th quarter. D.A. Davidson & CO. now owns 11,907 shares of the medical equipment provider’s stock worth $1,258,000 after acquiring an additional 3,175 shares during the last quarter. Finally, Citizens & Northern Corp increased its holdings in Zimmer Biomet by 5.0% in the 4th quarter. Citizens & Northern Corp now owns 12,811 shares of the medical equipment provider’s stock worth $1,353,000 after acquiring an additional 610 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Up 1.2 %

NYSE ZBH opened at $104.89 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The stock has a market cap of $20.88 billion, a P/E ratio of 23.57, a P/E/G ratio of 1.95 and a beta of 1.02. The stock’s fifty day moving average price is $105.86 and its 200-day moving average price is $107.47. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm earned $2.20 EPS. As a group, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Analyst Upgrades and Downgrades

Several research analysts have commented on ZBH shares. Truist Financial restated a “hold” rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Barclays dropped their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Royal Bank of Canada dropped their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. JMP Securities reissued a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Stifel Nicolaus upped their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.